C4 Therapeutics to Participate in Upcoming March Conferences
C4 Therapeutics (Nasdaq: CCCC) announced management will participate in two March 2026 healthcare conferences with live webcasts available for investors.
Rhea-AI Summary
C4 Therapeutics (Nasdaq: CCCC) announced management will participate in two March 2026 healthcare conferences with live webcasts available for investors. Management will present at the TD Cowen conference on March 3, 2026 at 11:50 AM ET and participate in Barclays on March 10, 2026 at 8:00 AM ET.
Webcasts will stream on the company’s Investor website, with archived replays available for about 90 days after each event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CCCC
On Feb 23, the day this news came out, CCCC closed 6.48% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- TD Cowen fireside chat time
- 11:50 AM ET
- TD Cowen 46th Annual Healthcare Conference on March 3, 2026
- TD Cowen conference date
- March 3, 2026
- Management presentation and fireside chat in Boston
- Barclays fireside chat time
- 8:00 AM ET
- Barclays 28th Annual Global Healthcare Conference on March 10, 2026
- Barclays conference date
- March 10, 2026
- Management fireside chat in Miami
- Webcast replay window
- 90 days
- Archived conference webcasts available to investors
Historical Context
-
Stock option inducement grant covering 162,880 shares to a new employee.
-
Management fireside chat at Guggenheim Biotech Summit with webcast access.
-
Inducement grant for 85,480 options vesting over four years.
-
Outlined cemsidomide development milestones, Phase 2 plans and cash runway to 2028.
-
Evercore healthcare conference fireside chat with 90-day webcast replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
targeted protein degradation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.
- TD Cowen 46th Annual Healthcare Conference:
- Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.
- Barclays 28th Annual Global Healthcare Conference:
- Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida.
The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. The archived replays of the webcasts will be available for approximately 90 days following the events.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.